Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opnurasib rollover study for participants continuing to benefit from prior Novartis studies
jRCT2031260238Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Open-label trial of opnurasib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (2 arms), sponsored by Novartis. Primary endpoints: Number of participants receiving opnurasib as single agent or in combination with other study treatments and Duration of exposure to study treatment. Started Jul 2026; status: recruiting.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260238.